tradingkey.logo
tradingkey.logo
Search

Twist Bioscience Corp

TWST
Add to Watchlist
99.240USD
-3.010-2.94%
Close 07/02, 13:00ETQuotes delayed by 15 min
6.17BMarket Cap
LossP/E TTM

More Details of Twist Bioscience Corp Company

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

Twist Bioscience Corp Info

Ticker SymbolTWST
Company nameTwist Bioscience Corp
IPO dateOct 31, 2018
CEOLeproust (Emily M)
Number of employees979
Security typeOrdinary Share
Fiscal year-endOct 31
Address681 Gateway Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone18007190671
Websitehttps://www.twistbioscience.com/
Ticker SymbolTWST
IPO dateOct 31, 2018
CEOLeproust (Emily M)

Company Executives of Twist Bioscience Corp

Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.47K
-6.20%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
99.15K
+5.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
65.04K
-10.77%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
28.78K
+17.70%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
23.50K
-5.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
21.34K
-70.08%
Dr. Melissa A. Starovasnik, Ph.D.
Dr. Melissa A. Starovasnik, Ph.D.
Independent Director
Independent Director
17.75K
-16.90%
Mr. Jan Johannessen
Mr. Jan Johannessen
Independent Director
Independent Director
13.28K
--
Mr. Adam Laponis
Mr. Adam Laponis
Chief Financial Officer
Chief Financial Officer
7.12K
-84.57%
Ms. Trynka Shineman Blake
Ms. Trynka Shineman Blake
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.47K
-6.20%
Mr. Keith L. Crandell
Mr. Keith L. Crandell
Independent Director
Independent Director
99.15K
+5.14%
Mr. Patrick John Finn, Ph.D.
Mr. Patrick John Finn, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
65.04K
-10.77%
Mr. Nelson C. Chan
Mr. Nelson C. Chan
Independent Director
Independent Director
28.78K
+17.70%
Ms. Paula Green
Ms. Paula Green
Senior Vice President - Human Resources
Senior Vice President - Human Resources
23.50K
-5.00%
Mr. Dennis Cho
Mr. Dennis Cho
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
21.34K
-70.08%

FAQs

Who are the top five shareholders of Twist Bioscience Corp?

The top five shareholders of Twist Bioscience Corp are: Dr. Emily M. Leproust, Ph.D.

How many institutions hold shares of Twist Bioscience Corp (TWST)?

As of 2026Q1, 592 institutions hold shares of Twist Bioscience Corp, with a combined market value of approximately 78.48M, accounting for 126.03% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -339291.00.

What is the biggest source of revenue for Twist Bioscience Corp?

In 2026Q1, the NGS applications business generated the highest revenue for Twist Bioscience Corp, amounting to 52.64M and accounting for 50.76% of total revenue.